Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network

P. Giorgi Rossi, E. Ferroni, S. Spila Alegiani, G. Pitter, O. Leoni, D. Cereda, M. Marino, M. Pellizzari, J. Sultana, G. Trifirò, M. Massari, the ITA-COVID19 working group
doi: https://doi.org/10.1101/2020.05.15.20103119
P. Giorgi Rossi
1Azienda Unità Sanitaria Locale – IRCC, Reggio Emilia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Ferroni
2Azienda Zero of the Veneto Region, Padua, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Spila Alegiani
3Pharmacoepidemiology Unit – Italian National Institute of Health, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stefania.spila@iss.it
G. Pitter
2Azienda Zero of the Veneto Region, Padua, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Leoni
4Department of Health of Lombardy Region, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Cereda
4Department of Health of Lombardy Region, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Marino
1Azienda Unità Sanitaria Locale – IRCC, Reggio Emilia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Pellizzari
2Azienda Zero of the Veneto Region, Padua, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Sultana
5Department of Biomedical and Dental Sciences and Morphofunctional Imaging – University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Trifirò
5Department of Biomedical and Dental Sciences and Morphofunctional Imaging – University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Massari
1Azienda Unità Sanitaria Locale – IRCC, Reggio Emilia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background COVID-19 case fatality rate in hospitalized patients varies across countries and studies, but reliable estimates specific for age, sex, and comorbidities are needed to design trials for COVID-19 interventions. Aim of this study is to provide population-based survival curves of hospitalized COVID-19 patients.

Methods A cohort study was conducted in Lombardy, Veneto, and Reggio Emilia using COVID-19 registries linked to hospital discharge databases containing patient clinical histories. All patients with positive SARS-CoV-2 RT-PCR test on oral/nasopharyngeal swabs hospitalized from 21st February to 21st April 2020 were identified. Kaplan Meier survival estimates were calculated at 14 and 30 days for death in any setting, stratifying by age, sex and Charlson Index.

Findings Overall 42,926 hospitalized COVID-19 patients were identified. Patients’ median age was 69 years (IQR: 57–79), 62·6% were males, 69·4% had a Charlson Index of 0. In total, 11,205 (26·1%) patients died over a median follow-up of 24 days (IQR: 10–35). Survival curves showed that 22·0% of patients died within 14 days and 27·6% within 30 days of hospitalization. Survival was higher in younger patients and in females. Younger patients with comorbidities had a lower survival than older ones with comorbidities.

Interpretation Over 27% of hospitalized COVID-19 patients died within one month in three areas of Northern Italy that were heavily affected by SARS-CoV-2 infection. Such a high fatality rate suggests that trials should focus on survival and have follow-up of at least one month.

Funding The study did not receive any external funding.

Evidence before this study Two recent systematic reviews with meta-analyses report case fatality rates of three to four percent in COVID-19 patients. Most studies on hospitalized cohorts report only slightly higher figures. These figures do not correspond to those derived from routinely collected clinical data in most European countries, reporting a 10% case fatality rate which has been increasing over time since the epidemic started.

Robust and precise survival estimates of hospitalized COVID-19 patients which take into account prognostic factors such as age, sex and burden of comorbidities are needed to design appropriate phase II and phase III clinical studies of drugs targeting COVID-19.

Added value of this study In this study we present the first survival estimates by age, sex and Charlson index for a large population-based cohort of Italian hospitalized COVID-19 patients.

Implications of all the available evidence Over 27% of COVID-19 patients died within one month from hospital admission. Such a high fatality rate suggests that studies should prioritize mortality as primary outcome. Furthermore, we found that the fatality rate reaches a plateau 30 days after hospitalization, suggesting that studies should have at least one month of follow up to observe deaths; shorter follow-up could lead to overestimation of treatment benefits.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study did not receive any external funding.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ITA-COVID19 working group Italian National Institute of Health (Italy): Stefania Spila Alegiani, Francesca Menniti Ippolito, Roberto Da Cas, Marco Massari, Graziano Onder, Patrizio Pezzotti; University of Messina – Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina (Italy) & Italian Society of Pharmacology, Milan (Italy): Gianluca Trifirò, Janet Sultana, Valentina Ientile, Salvatore Crisafulli; Azienda Unità Sanitaria Locale – IRCCS, Reggio Emilia (Italy): Paolo Giorgi Rossi, Roberto Grilli, Giulio Formoso, Massimiliano Marino, Massimo Vicentini; Lombardy Region – Directorate General for Health, Milan (Italy): Olivia Leoni, Danilo Cereda, Monica Ludergnani, Annalisa Bodina, Ambra Castrofino, Francesca Grosso, Gabriele del Castillo, Marcello Tirani; Veneto Region – Azienda Zero, Padova (Italy): Eliana Ferroni, Gisella Pitter, Michele Pellizzari, Manuel Zorzi, Elena Narne, Ugo Fedeli, Mario Saia.

Data Availability

Data will be updated periodically. Aggregate data are available upon submission of a request which describes the research objectives and a protocol for analyses to the local competent authorities: for Lombardy, queries should be submitted to a specific COVID-19 Committee, identified by the Directorate General for Health (under DDG n. 3019/2020), e-mail accessodatic19{at}regione.lombardia.it; for Veneto to the Health Direction of the Azienda Zero, e-mail: direzione.sanitaria{at}azero.veneto.it; for Reggio Emilia to the Comitato Etico Area Vasta Emilia Nord, Reggio Emilia office, e-mail: mariafrancesca.paolo{at}ausl.re.it. Data will be available at least for seven years from the approval of the study.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 19, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network
P. Giorgi Rossi, E. Ferroni, S. Spila Alegiani, G. Pitter, O. Leoni, D. Cereda, M. Marino, M. Pellizzari, J. Sultana, G. Trifirò, M. Massari, the ITA-COVID19 working group
medRxiv 2020.05.15.20103119; doi: https://doi.org/10.1101/2020.05.15.20103119
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network
P. Giorgi Rossi, E. Ferroni, S. Spila Alegiani, G. Pitter, O. Leoni, D. Cereda, M. Marino, M. Pellizzari, J. Sultana, G. Trifirò, M. Massari, the ITA-COVID19 working group
medRxiv 2020.05.15.20103119; doi: https://doi.org/10.1101/2020.05.15.20103119

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (862)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1758)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10318)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1681)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3853)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)